29 November 2022 – Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative.

Walder Wyss acted as Swiss legal advisor to Pfizer in this transaction. The Walder Wyss deal team included Urs Schenker (Counsel, Corporate/M&A), Samuel Lieberherr (Managing Associate, Corporate/M&A) and Timon Nydegger (Senior Associate, Corporate/M&A).